The Italian Registry of Patients With Chronic Obstructive Pulmonary Disease

Summary

Chronic obstructive pulmonary disease (COPD) is a treatable but debilitating medical condition associated with persistent symptoms and chronic airflow obstruction. Despite the availability of multiple therapeutic options, COPD is the third leading cause of death worldwide and has a substantial socioeconomic impact.

The present real life study is aimed at describing the clinical and functional characteristics, treatment patterns, impact of exacerbations and comorbidities and their association with mortality in a large cohort of Italian patients with COPD.

Conditions

• COPD
• COPD Exacerbation Acute
• Comorbid Chronic Lung Disease on Heart Failure
• Mortality
• Cardiovascular Diseases
• Cardiovascular Events
• COPD Prevalance

Interventions

OTHER

Pharmacological treatment

Pharmacological and non pharmacological treatments will be assessed and monitored during the retrospective and prospective phase, and will include: * bronchodilators, inhaled steroids and their combinations * mucolytics * biologic therapies for COPD * roflumilast * pulmonary rehabilitation

OTHER

Pharmacological treatment

All pharmacological and non pharmacological treatments for COPD will be assessed and monitored during the retrospective and prospective phase of the study, and will include: * inhaled bronchodilators (long term beta-2 agonists and cholinergic antagonists), inhaled corticosteroids and their combinations * mucolytics * biologics for COPD (monoclonal antibodies) * roflumilast * chronic oral azythromicin * pulmonary rehabilitation * oxygen therapy * non invasive/invasive ventilation

Sponsors & Collaborators

• University of Genova

  collaborator OTHER

• University of Pavia

  collaborator OTHER

• Azienda Ospedaliera Universitaria Integrata Verona

  collaborator OTHER

• University Magna Graecia

  collaborator OTHER

• University of Rome Tor Vergata

  collaborator OTHER

• Università degli Studi di Sassari

  collaborator OTHER

• University of Palermo

  collaborator OTHER

• University of Turin, Italy

  collaborator OTHER

• University Hospital Verona, Italy

  collaborator UNKNOWN

• University Hospital of Ferrara

  collaborator OTHER

• Societa Italiana di Pneumologia

  collaborator OTHER

• Italian Association of Hospital Pneumologists

  collaborator OTHER

• University of Milan

  lead OTHER

Eligibility

Min Age

40 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2024-09-30

Primary Completion

2035-12-31

Completion

2035-12-31

Countries

• Italy

Study Locations